Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29

Drug approval Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Eli Lilly reports Q3 earnings on October 29 after five consecutive quarters of beating EPS estimates.

πŸ’° Q2 revenue surged 47.7% to $22.97 billion, with Mounjaro sales up 91% and Zepbound up 46%.

πŸ“‰ Q3 EPS estimates fell from $9.87 to $6.67 due to acquired IPR&D charges impacting non-GAAP metrics.

πŸš€ Management raised full-year revenue guidance twice this year to a range of $85 billion to $87 billion.

🌍 International tirzepatide demand grew 172% in Q2 following China's NRDL inclusion, supporting potential further guidance raises.

πŸ“‰ U.S. pricing for Mounjaro fell 9% excluding rebates, but management expects volume growth to offset the impact.

πŸ’Š Foundayo generated $98 million in its launch quarter with volumes almost doubling from a month earlier.

πŸ”¬ CEO David Ricks stated Lilly has all clinical data needed for retatrutide BLA filing expected in Q1 2027.

βš–οΈ Lilly's Zepbound outperformed Novo Nordisk's Wegovy HD in weight loss, though competitor pricing poses margin risks.

πŸ“‰ Shares gained 19.07% year-to-date despite recent downward revisions to Q3 EPS estimates by analysts.

Bullish Signals
  • Eli Lilly achieved a five-quarter winning streak of EPS beats, demonstrating consistent operational execution and market dominance.
  • Mounjaro sales surged 91% to $9.94 billion in the last quarter, solidifying its position as a top-tier growth driver.
  • Zepbound revenue grew 46% to $4.93 billion, expanding the company's obesity treatment portfolio effectively.
  • Management raised full-year revenue guidance for the second time this year to a range of $85 billion to $87 billion.
  • International tirzepatide demand exploded with 172% growth in Q2 following regulatory inclusion in China.
  • Foundayo generated $98 million in its launch quarter, indicating successful diversification beyond the core franchise.
  • The company possesses all necessary clinical data for retatrutide, positioning it for a potential BLA filing in Q1 2027.
  • Zepbound demonstrated superior weight loss efficacy compared to Novo Nordisk's Wegovy HD in indirect comparisons.
Risk Factors
  • Q3 EPS estimates dropped sharply from $9.87 to $6.67 due to significant acquired IPR&D charges affecting non-GAAP earnings.
  • U.S. pricing for Mounjaro declined by 9% excluding rebates, creating pressure on revenue per unit despite volume growth plans.
  • Novo Nordisk's aggressive pricing moves present a real and explicit risk to Eli Lilly's future margins in the obesity market.
  • The stock has already rallied nearly 20% year-to-date, leaving little room for error if Q3 results fail to meet elevated expectations.
Full Analysis
Eli Lilly (LLY) is set to report third-quarter earnings on October 29, following a streak of five consecutive EPS beats and a stock price surge of nearly 20% year-to-date. The company's financial performance remains heavily anchored by its blockbuster tirzepatide franchise, with Mounjaro sales climbing 91% to $9.94 billion and Zepbound growing 46% to $4.93 billion in the prior quarter. Despite strong revenue growth of 47.7% to $22.97 billion last quarter, Wall Street consensus estimates for Q3 EPS have dropped significantly from $9.87 to $6.67 due to acquired IPR&D charges. Management has raised full-year revenue guidance twice this year to a range of $85 billion to $87 billion, though the consensus already sits higher at $88.68 billion. Three key catalysts are driving investor attention ahead of the earnings release: potential for another guidance raise driven by international demand, volume growth offsetting recent U.S. price declines, and progress on next-generation weight loss drugs like retatrutide. While Lilly claims Zepbound outperforms Novo Nordisk's Wegovy HD in indirect comparisons, pricing pressure from competitors remains a noted margin risk.